PL2749282T3 - Sposób leczenia migotania przedsionków - Google Patents

Sposób leczenia migotania przedsionków

Info

Publication number
PL2749282T3
PL2749282T3 PL14161300T PL14161300T PL2749282T3 PL 2749282 T3 PL2749282 T3 PL 2749282T3 PL 14161300 T PL14161300 T PL 14161300T PL 14161300 T PL14161300 T PL 14161300T PL 2749282 T3 PL2749282 T3 PL 2749282T3
Authority
PL
Poland
Prior art keywords
atrial fibrillation
treating atrial
treating
fibrillation
atrial
Prior art date
Application number
PL14161300T
Other languages
English (en)
Inventor
Charles Antzelevitch
Luiz Belardinelli
Alexander Burashnikov
John Shryock
Dewan Zeng
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43736345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2749282(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PL2749282T3 publication Critical patent/PL2749282T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
PL14161300T 2009-12-21 2010-12-20 Sposób leczenia migotania przedsionków PL2749282T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28873909P 2009-12-21 2009-12-21
EP14161300.0A EP2749282B1 (en) 2009-12-21 2010-12-20 Method of treating atrial fibrillation
EP20100798436 EP2515900B1 (en) 2009-12-21 2010-12-20 Method of treating atrial fibrillation

Publications (1)

Publication Number Publication Date
PL2749282T3 true PL2749282T3 (pl) 2018-01-31

Family

ID=43736345

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10798436T PL2515900T3 (pl) 2009-12-21 2010-12-20 Sposób leczenia migotania przedsionków
PL14161300T PL2749282T3 (pl) 2009-12-21 2010-12-20 Sposób leczenia migotania przedsionków

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10798436T PL2515900T3 (pl) 2009-12-21 2010-12-20 Sposób leczenia migotania przedsionków

Country Status (36)

Country Link
US (3) US8513254B2 (pl)
EP (2) EP2515900B1 (pl)
JP (2) JP5723889B2 (pl)
KR (2) KR20160108611A (pl)
CN (3) CN104688739A (pl)
AP (1) AP3536A (pl)
AR (1) AR079552A1 (pl)
AU (1) AU2010339753B2 (pl)
BR (1) BR112012015499A2 (pl)
CA (1) CA2784028C (pl)
CL (1) CL2012001597A1 (pl)
CR (1) CR20120353A (pl)
CY (1) CY1116511T1 (pl)
DK (1) DK2515900T3 (pl)
EA (2) EA201691336A1 (pl)
EC (1) ECSP12012004A (pl)
ES (2) ES2646603T3 (pl)
HR (1) HRP20150644T1 (pl)
HU (1) HUE026916T2 (pl)
IL (1) IL220152A (pl)
ME (1) ME02179B (pl)
MX (2) MX344329B (pl)
NO (1) NO2749282T3 (pl)
NZ (2) NZ627181A (pl)
PE (1) PE20121520A1 (pl)
PL (2) PL2515900T3 (pl)
PT (2) PT2749282T (pl)
RS (1) RS54118B1 (pl)
SG (3) SG181541A1 (pl)
SI (2) SI2515900T1 (pl)
SM (1) SMT201500171B (pl)
TW (1) TWI508726B (pl)
UA (1) UA109887C2 (pl)
UY (1) UY33119A (pl)
WO (1) WO2011084733A1 (pl)
ZA (1) ZA201204608B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04011530A (es) 2002-05-21 2005-08-15 Cv Therapeutics Inc Administracion de un inhibidor de acido graso parcial tal como ranolazina para el tratamiento de diabetes.
US8952034B2 (en) 2009-07-27 2015-02-10 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
EP3760180B1 (en) 2009-07-29 2024-10-30 ICU Medical, Inc. Fluid transfer devices
WO2011135582A2 (en) * 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of dronedarone
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
CA2834164A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused benzoxazinones as ion channel modulators
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (pl) 2011-07-01 2018-04-28
US20150045305A1 (en) * 2012-01-27 2015-02-12 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US20140364417A1 (en) * 2013-05-03 2014-12-11 Gilead Sciences, Inc. Method of treating atrial fibrillation
SG11201600104VA (en) * 2013-08-02 2016-02-26 Gilead Sciences Inc Pharmaceutical compositions of ranolazine and dronedarone
WO2015073922A2 (en) 2013-11-15 2015-05-21 Northwestern University Inhibition of oxidative stress in atrial fibrillation
AU2014364783B2 (en) 2013-12-19 2017-01-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
CN104951870B (zh) * 2015-06-01 2018-11-13 南通科瑞斯生物医药科技有限公司 药物临床前心脏风险评估方法
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
AU2017228371A1 (en) 2016-03-04 2018-09-13 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
US10575744B2 (en) 2017-02-24 2020-03-03 Medtronic Cryocath Lp Pericardial balloon mapping
US10799703B2 (en) * 2017-12-22 2020-10-13 Medtronic, Inc. Evaluation of his bundle pacing therapy
EP3530182B1 (en) * 2018-02-27 2020-12-09 Nokia Technologies Oy Apparatus and method for determining a change in left ventricular twist of a subject's heart
CN120053445A (zh) 2018-07-16 2025-05-30 吉利德科学公司 用于治疗hiv的衣壳抑制剂
AU2020212054B2 (en) * 2019-01-24 2025-06-12 Northwestern University Gene therapy treatment of atrial fibrillation
US11712188B2 (en) * 2019-05-07 2023-08-01 Medtronic, Inc. Posterior left bundle branch engagement
KR102891439B1 (ko) 2019-08-01 2025-11-25 인카다 테라퓨틱스, 인크. 항부정맥 제제
DK4445900T3 (da) 2021-12-03 2025-08-18 Gilead Sciences Inc Terapeutiske forbindelser til hiv-virusinfektion
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
ATE142497T1 (de) 1989-06-23 1996-09-15 Syntex Inc Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
FR2764800B1 (fr) 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
AU2001278045B2 (en) * 2000-07-27 2006-08-03 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
FR2817750B1 (fr) 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
AU2002231175A1 (en) 2000-12-27 2002-07-08 Focal, Inc. Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart
IL159614A0 (en) * 2001-07-20 2004-06-01 Karobio Ab Benzofuran derivatives and pharmaceutical compositions containing the same
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
CA2593593A1 (en) 2005-01-06 2006-07-13 Cv Therapeutics, Inc. Sustained release pharmaceutical formulations comprising ranolazine
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
EP2117509A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
EP2133074A1 (en) * 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation
EP2337559A2 (en) 2008-09-04 2011-06-29 Gilead Sciences, Inc. Method of treating atrial fibrillation

Also Published As

Publication number Publication date
SG10201710751TA (en) 2018-02-27
PT2749282T (pt) 2017-11-15
SMT201500171B (it) 2015-09-07
CA2784028C (en) 2016-08-23
SI2515900T1 (sl) 2015-07-31
US9056108B2 (en) 2015-06-16
RS54118B1 (sr) 2015-12-31
ECSP12012004A (es) 2012-08-31
IL220152A (en) 2016-11-30
PT2515900E (pt) 2015-07-30
AP2012006331A0 (en) 2012-06-30
MX344329B (es) 2016-12-13
EP2515900B1 (en) 2015-04-29
ME02179B (me) 2015-10-20
UY33119A (es) 2011-07-29
JP2015057449A (ja) 2015-03-26
MX2012007052A (es) 2012-07-30
PL2515900T3 (pl) 2015-10-30
SI2749282T1 (sl) 2017-12-29
SG181541A1 (en) 2012-07-30
US20130317038A1 (en) 2013-11-28
WO2011084733A1 (en) 2011-07-14
ES2540093T3 (es) 2015-07-08
AU2010339753B2 (en) 2015-01-22
CN104688739A (zh) 2015-06-10
JP5723889B2 (ja) 2015-05-27
HK1170675A1 (en) 2013-03-08
TW201136586A (en) 2011-11-01
IL220152A0 (en) 2012-07-31
EA025445B1 (ru) 2016-12-30
BR112012015499A2 (pt) 2016-05-03
US20140323493A1 (en) 2014-10-30
ZA201204608B (en) 2013-02-27
KR20120107995A (ko) 2012-10-04
CY1116511T1 (el) 2017-03-15
SG10201408528RA (en) 2015-04-29
AP3536A (en) 2016-01-13
CN102665713A (zh) 2012-09-12
EP2515900A1 (en) 2012-10-31
CL2012001597A1 (es) 2013-06-28
AU2010339753A1 (en) 2012-07-12
EP2749282B1 (en) 2017-08-09
PE20121520A1 (es) 2012-11-26
CN104147010A (zh) 2014-11-19
CA2784028A1 (en) 2011-07-14
CN102665713B (zh) 2015-02-18
AR079552A1 (es) 2012-02-01
EP2749282A1 (en) 2014-07-02
NZ627181A (en) 2016-02-26
HRP20150644T1 (hr) 2015-07-31
US8513254B2 (en) 2013-08-20
HUE026916T2 (en) 2016-08-29
NZ600718A (en) 2014-08-29
ES2646603T3 (es) 2017-12-14
KR20160108611A (ko) 2016-09-19
CR20120353A (es) 2014-10-07
NO2749282T3 (pl) 2018-01-06
US8754087B2 (en) 2014-06-17
EA201290451A1 (ru) 2013-01-30
US20110183990A1 (en) 2011-07-28
TWI508726B (zh) 2015-11-21
JP2013515007A (ja) 2013-05-02
UA109887C2 (uk) 2015-10-26
EA201691336A1 (ru) 2017-05-31
DK2515900T3 (en) 2015-07-27

Similar Documents

Publication Publication Date Title
AP3536A (en) Method of treating atrial fibrillation
EP2558014A4 (en) Methods and devices for treating atrial fibrillation
EP2421607A4 (en) DEVICE AND METHOD FOR PROOFING AND TREATING PREVIOUS LAYOUMS
IL208354A0 (en) Methods of treatment
EP2313103A4 (en) PROCESS FOR TREATING A BLÉPHARITE
IL214664A0 (en) Methods of treating hair related conditions
GB201018147D0 (en) Method of treatment
PL2501381T3 (pl) Leczenie migotania przedsionków
GB201003920D0 (en) Method of treatment
EP2300496A4 (en) ATHEROSCLEROSIS TREATMENT METHODS
ZA201108493B (en) Method of treating hair
ZA201005206B (en) Method of treating hair
GB201018149D0 (en) Method of treatment
EP2585103A4 (en) METHOD OF TREATMENT
IL216456A0 (en) Method of treating frailty
GB201020015D0 (en) Method of treatment
EP2424539A4 (en) PROCESS FOR TREATING DEPRESSION
EP2306838A4 (en) METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS
HK1158972A (en) Method of treating atrial fibrillation
AU2011904917A0 (en) Method for preventing and/or treating atrial fibrillation
HK1182299A (en) Methods and devices for treating atrial fibrillation
GB0823435D0 (en) Method of treatment
GB0921823D0 (en) Method of treatment
GB0909807D0 (en) Method of treatment
GB0904164D0 (en) Method of treatment